Next-gen cancer drug here

South Australian researchers at the forefront of developing “the biggest breakthrough this century” in treatment for chronic myeloid leukaemia (CML) are heralding a decision to allow patients here easy access to it.

The new drug, which targets abnormal cancer-generating proteins in cells, has been 25 years in the making, with SA experts partnering with a Switzerland-based pharmaceutical company to help fine-tune and test the emerging treatment.

This month Asciminib, which comes in tablet form and is sold under the brand name Scemblix, has been added to Australia’s PBS schedule, effectively taking it from a trial drug to a recognised treatment option.

Read the full article published in the Sunday Mail.